These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 29250983)

  • 1. The impact of non-genetic heterogeneity on cancer cell death.
    Inde Z; Dixon SJ
    Crit Rev Biochem Mol Biol; 2018 Feb; 53(1):99-114. PubMed ID: 29250983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer cell metabolism connects epigenetic modifications to transcriptional regulation.
    Morrison AJ
    FEBS J; 2022 Mar; 289(5):1302-1314. PubMed ID: 34036737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vitro model of tumor heterogeneity resolves genetic, epigenetic, and stochastic sources of cell state variability.
    Hayford CE; Tyson DR; Robbins CJ; Frick PL; Quaranta V; Harris LA
    PLoS Biol; 2021 Jun; 19(6):e3000797. PubMed ID: 34061819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment.
    Rodriguez-Nieto S; Zhivotovsky B
    Curr Pharm Des; 2006; 12(34):4411-25. PubMed ID: 17168751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic lethal vulnerabilities of cancer.
    Fece de la Cruz F; Gapp BV; Nijman SM
    Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance, epigenetics, and tumor cell heterogeneity.
    Hoey T
    Sci Transl Med; 2010 Apr; 2(28):28ps19. PubMed ID: 20410528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connections between metabolism and epigenetics in cancers.
    Thakur C; Chen F
    Semin Cancer Biol; 2019 Aug; 57():52-58. PubMed ID: 31185282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into new mechanisms and models of cancer stem cell multidrug resistance.
    Garcia-Mayea Y; Mir C; Masson F; Paciucci R; LLeonart ME
    Semin Cancer Biol; 2020 Feb; 60():166-180. PubMed ID: 31369817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How the Warburg effect supports aggressiveness and drug resistance of cancer cells?
    Icard P; Shulman S; Farhat D; Steyaert JM; Alifano M; Lincet H
    Drug Resist Updat; 2018 May; 38():1-11. PubMed ID: 29857814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.
    Nijman SMB
    Trends Cancer; 2020 Jun; 6(6):454-461. PubMed ID: 32460001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies.
    Wajapeyee N; Gupta R
    Cancer Res; 2021 Nov; 81(22):5589-5595. PubMed ID: 34531319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential.
    He S; Moutaoufik MT; Islam S; Persad A; Wu A; Aly KA; Fonge H; Babu M; Cayabyab FS
    Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188355. PubMed ID: 32135169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic targeting of cell death pathways.
    Mansilla S; Llovera L; Portugal J
    Anticancer Agents Med Chem; 2012 Mar; 12(3):226-38. PubMed ID: 22263795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNAs in cancer drug resistance development.
    Majidinia M; Yousefi B
    DNA Repair (Amst); 2016 Sep; 45():25-33. PubMed ID: 27427176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-carbon metabolism for cancer diagnostic and therapeutic approaches.
    Asai A; Konno M; Koseki J; Taniguchi M; Vecchione A; Ishii H
    Cancer Lett; 2020 Feb; 470():141-148. PubMed ID: 31759958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.